VEGF binding to the VEGF receptor induces phosphorylation of tyrosine kinase residues of the intracellular domain. Ephrin-B2 colocalizes in the membrane of endothelial cells in blood and lymphatic ...

We hypothesized that 1) VEGF-A and its main functional receptor, VEGFR-2, are expressed in the fetal intestines; 2) one or both of these proteins are up-regulated in association with advancing ...

The HER family receptors form a signaling network that contributes to cancer progression. Angiogenesis plays a major role in cancer and VEGF-targeted agents have been shown to be useful in ...

Sorafenib is an oral tyrosine kinase inhibitor able to inhibit VEGF receptors 1, 2 and 3, PDGF receptors α and β, RET, Flt3, c-KIT and the RAF kinase and MAPK pathways. Over 10,000 patients have ...

The phase 1 clinical trial is a multicenter, open-label, dose-escalation study to assess drug safety via intravitreal ...

Health Canada has granted market authorisation to Takeda Canada for FRUZAQLA (fruquintinib) capsules to treat adults with ...

The following is a summary of “Lenvatinib and immune-checkpoint inhibitors in hepatocellular carcinoma: mechanistic insights, clinical efficacy, and future perspectives,” published in the December ...

US-based biotechnology company Ocugen has dosed the first subject in a multicentre Phase I trial of OCU200 for diabetic ...

Opthea Limited Sponsored ADR (OPT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst ...

ImmuneOnco announced dosing of first patient in its recently initiated Phase 1b/2 clinical trial of IMM2510/SYN-2510 in ...